ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that Dr. Michael Bristow, President and Chief Executive Officer, will be a featured panelist at the Personalized Medicine Coalition’s Conference, New Frontiers in Personalized Medicine: Cardiovascular Research and Clinical Care, January 6, 2011 at the George Washington University in Washington, D.C. Dr. Bristow will speak on “Development of New Treatments and Treatment Strategies for Heart Failure.”

“Improving outcomes, increasing efficacy and decreasing adverse events is critical,” said Edward Abrahams, President of the Personalized Medicine Coalition. “Cardiovascular disease is the number one cause of death in the United States and poised to become the number one cause of death globally.”

More information about the conference is available at:

About the Personalized Medicine Coalition

The Personalized Medicine Coalition, representing a broad spectrum of academic, industrial, patient, provider and payer communities, seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. For more information please visit

About ARCA biopharma

ARCA biopharma is dedicated to developing genetically targeted therapies for heart failure and other cardiovascular diseases. The Company's lead product candidate, Gencaro TM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted heart failure treatment. ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for Gencaro. For more information please visit

Safe Harbor Statement

This press release and the anticipated presentation contain "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the ability of genetic variations to predict individual patient response to Gencaro, the potential for Gencaro to be the first genetically targeted heart failure treatment and statements regarding the potential for personalized medicine to improve outcomes, increase efficacy, or decrease adverse events in cardiovascular patients. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company's financial resources and whether they will be sufficient to meet the Company's business objectives and operational requirements; the protection and market exclusivity provided by the Company’s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA’s filings with the SEC, including without limitation the Company’s annual report on Form 10-K for the year ended December 31, 2009 and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements.

Copyright Business Wire 2010